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Gene S. Fisch2,*I am delighted to be given the honor of introducing the
recipient of the William Allan Award for 2015, Kay E.
Davies.
Kay was born in theWest Midlands of England, in Stour-
bridge, a village not far from Birmingham. Kay excelled at
math, which she thought to have inherited from her
father, a machinist for British Leyland. Kay was also inter-
ested in biology: her mother was an avid gardener and
botanist who also worked part time at the Glass Museum
in Stourbridge. Where Kay went to school, one studied
either biology or Latin; and if one did not study Latin,
one could not enter Oxbridge. And so, Kay chose Latin
and dropped biology. After sixth form, Kay went to Somer-
ville College to read chemistry, a path pursued by another
well-known Englishwoman—Margaret Thatcher. Somer-
ville was one of the first women’s colleges at Oxford. It
was founded in 1879 and first named Somerville Hall for
the then recently deceased Scottish mathematician Mary
Somerville. Somerville was admired as a scholar and for
her conviction that women should have equality in terms
of suffrage, as well as access to education.
As a scientist, Kay’s earliest investigations involved the
transcription and structure of nucleolar chromatin in
what are commonly called ‘‘slime molds,’’ which are used
as a model organism for studying cell motility.1 Later,
with colleagues Peter Harper and Bob Williamson, Kay
worked with recombinant DNA sequences on the human
X chromosome as markers for chromosomal mapping of
X-linked diseases.2 In the 1980s, her pursuit of X-linked
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The Amegeneticists to develop linkage maps of X-linked mental
retardation (XLMR). Her investigations in XLMR led to
research in fragile X syndrome, on which she carried out
physical mapping studies with many other molecular
geneticists.
I first met Kay at the Third International Workshop on
Fragile X and X-Linked Mental Retardation in Troina, Italy,
in September 1987. It was my first big small conference,
and I was thrilled to meet all the scientists whose articles
I had read as a young researcher of fragile X and autism.
Many of those researchers, e.g., Jean-Louis Mandel, Grant
Sutherland, and Steve Warren, went on to make important
scientific advances in genetics in general and in fragile X in
particular.
Regarding fragile X, the breakthrough in research came
in May 1991, when Kay, Jean-Louis Mandel, and Grant Su-
therland simultaneously published their investigations3–5
defining the region of the fragile site at Xq27.3, where
the mutation of FMR1 resides. Their findings, along with
the discovery of FMR1 itself, were presented at the Fifth In-
ternational Workshop on Fragile X and X-Linked Mental
Retardation in Strasbourg, France, in August 1991. The
FMR1 mutation, a CGG triplet-repeat disorder, was a ge-
netic breakthrough and the first of its kind to be detected,
the importance of which led to the discovery of many
other triplet-repeat disorders.
Having published 48 peer-reviewed manuscripts on the
topic, Kay continued to study the FMR1 mutation until
2004. Her lab also went on to pioneer research in the
‘‘other fragile X’’ mutation in FRAXE.6 Mark Hirst and
Samantha Knight, two junior researchers she supervised
while investigating fragile X, went on to become senior re-
searchers in genetics in their own right.
While simultaneously investigating fragile X, Kay also
labored intensively on another X-linked disorder,
Duchennemuscular dystrophy (DMD). Kay’s group cloned
the first chromosome-enriched library and used this to
develop markers7 for the first prenatal diagnosis of DMD.
Her group was one of the first to develop a physical map
of the DMD gene8 and showed that it covers more than a
megabase of DNA. Their researches also revealed that the
gene has hotspots for the deletion, which allowed for the
development of rapid deletion tests for the disorder.9,10
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is compatible with large deletions of the central rod
domain of the DMD protein, dystrophin.11 Although
initially met with skepticism, her group showed that mini-
genes modeled on this large deletion could function as a
replacement for the full-length gene.12 Dystrophin mini-
genes are now used worldwide in gene-therapy protocols.
Her group’s discovery of utrophin,13 a gene closely related
to dystrophin, and the subsequent development of a dys-
trophin-utrophin double-knockout mouse model,14 is
now used in testing DMD therapies. Her recent collabora-
tion with Summit Therapeutics is intended to develop
drugs to increase utrophin in DMD patients.15 As a result
of her investigations in DMD, her group at Oxford has
an international reputation in the field of DMD research.
Most recently, her work with survival motor neuron pro-
tein (SMN) in amyotrophic lateral sclerosis (ALS) found
that treatment with SMN slows motor neuron loss and
the onset of locomotor deficit in the ALS mouse.16
Kay’s appointments and honors are manifold. She is the
Dr. Lee’s Professor of Anatomy at Oxford University and is
a fellow at Hertford College. She is also director of theMed-
ical Research Council (MRC) Functional Genomics Unit
and deputy chair of the Wellcome Trust. Kay was the first
European to serve on the board of ASHG. Earlier in her
career, while still at Oxford, she was appointed head of
the MRC Clinical Science Centre at Hammersmith Hospi-
tal, London, and commuted back and forth between her
lab at Oxford and London. In 2003, Kay was elected fellow
of the Royal Society. Having previously been awarded
Commander of the Order of the British Empire, she was
advanced to Dame Commander (First Class) in 2008,
which is to say, ‘‘There is nothing like a Dame.’’
For nearly four decades, Kay has been an ardent
researcher in molecular genetics. She has published 384
peer-reviewed articles in the most prestigious journals of
genetics, biology, and neuroscience. Her accomplishments
are clearly praiseworthy of the highest acknowledgment.
Please join me in congratulating her as the recipient of
the William Allan Award for 2015.References
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